secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001683168-26-000959
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical Q3 FY2026: cash $7.0M; operating loss $2.06M up 13.6% YoY
-------------------------------------------------------------------------

- Cash balance of ~$7.0M as of Dec 31, 2025; no revenue reported.
- Q3 operating loss of $2.06M vs $1.81M in prior year, driven by higher payroll costs.
- Nine-month operating expenses down 26.9% to $5.36M from $7.34M YoY.
- Cohort 2 of Australian oncology trial progressing; Hemopurifier compatibility study with SLAMB system underway.
- Preclinical Long COVID data published on bioRxiv; submitted for peer review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316826000959/0001683168-26-000959-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316826000959/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-000959

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer